Therefore, how a patient would response to platinum therapy is dependent not only on the occurrence of mutations that functionally inactivate BRCA1/2 but also to a large degree on other cellular mechanisms such as ion transport pathways that influence the dynamics of the drug within the tumor. The gene discussed is BRCA1; the disease is neoplasm.